Hyperlipidemias  >>  Isentress (raltegravir)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Isentress (raltegravir) / Merck (MSD)
NCT02097108 / 2013-001564-37: Changes in Lipids and Lipoproteins in HIV Infected Women After Switch From Protease Inhibitor to Raltegravir

Completed
2
11
Europe
Raltegravir
Arbeitsgemeinschaft medikamentoese Tumortherapie, Merck Sharp & Dohme LLC
HIV Infections
12/15
12/15

Download Options